UTMB study shows common antibody therapy has anti-SARS-CoV-2 Antibodies
Scienmag
APRIL 25, 2022
GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. Latest News Antibodies antibody antiSARSCoV2 common shows study therapy UTMB
Let's personalize your content